VNRX Stock Overview
VolitionRx Limited, a multi-national epigenetics company, engages in the development of blood tests to help diagnose and monitor a range of cancers, and sepsis and COVID-19 in the United States and internationally.
| Snowflake Score | |
|---|---|
| Valuation | 2/6 |
| Future Growth | 2/6 |
| Past Performance | 0/6 |
| Financial Health | 2/6 |
| Dividends | 0/6 |
Rewards
Risk Analysis
+ 2 more risks
VolitionRx Limited Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | US$0.89 |
| 52 Week High | US$2.10 |
| 52 Week Low | US$0.55 |
| Beta | 1.35 |
| 1 Month Change | 18.72% |
| 3 Month Change | -16.81% |
| 1 Year Change | -46.21% |
| 3 Year Change | -72.86% |
| 5 Year Change | -73.59% |
| Change since IPO | -70.33% |
Recent News & Updates
Recent updates
Do Institutions Own VolitionRx Limited (NYSEMKT:VNRX) Shares?
Mar 17
This Insider Has Just Sold Shares In VolitionRx Limited (NYSEMKT:VNRX)
Feb 10
Market Sentiment Around Loss-Making VolitionRx Limited (NYSEMKT:VNRX)
Jan 27Have Insiders Been Selling VolitionRx Limited (NYSEMKT:VNRX) Shares This Year?
Dec 29What Type Of Shareholders Own The Most Number of VolitionRx Limited (NYSEMKT:VNRX) Shares?
Nov 30Shareholder Returns
| VNRX | US Medical Equipment | US Market | |
|---|---|---|---|
| 7D | 44.2% | 1.6% | 1.0% |
| 1Y | -46.2% | -1.4% | 21.9% |
Return vs Industry: VNRX underperformed the US Medical Equipment industry which returned -0.5% over the past year.
Return vs Market: VNRX underperformed the US Market which returned 24.9% over the past year.
Price Volatility
| VNRX volatility | |
|---|---|
| VNRX Average Weekly Movement | 16.7% |
| Medical Equipment Industry Average Movement | 7.3% |
| Market Average Movement | 6.0% |
| 10% most volatile stocks in US Market | 16.8% |
| 10% least volatile stocks in US Market | 3.0% |
Stable Share Price: VNRX's share price has been volatile over the past 3 months.
Volatility Over Time: VNRX's weekly volatility (17%) has been stable over the past year, but is still higher than 75% of US stocks.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| n/a | 110 | Cameron Reynolds | www.volition.com |
VolitionRx Limited, a multi-national epigenetics company, engages in the development of blood tests to help diagnose and monitor a range of cancers, and sepsis and COVID-19 in the United States and internationally. The company offers Nu Q Vet, a cancer screening test for dogs and other animals; Nu
VolitionRx Limited Fundamentals Summary
| VNRX fundamental statistics | |
|---|---|
| Market cap | US$73.05m |
| Earnings (TTM) | -US$35.32m |
| Revenue (TTM) | US$775.30k |
94.2x
P/S Ratio-2.1x
P/E RatioIs VNRX overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| VNRX income statement (TTM) | |
|---|---|
| Revenue | US$775.30k |
| Cost of Revenue | US$0 |
| Gross Profit | US$775.30k |
| Other Expenses | US$36.09m |
| Earnings | -US$35.32m |
Last Reported Earnings
Dec 31, 2023
Next Earnings Date
n/a
| Earnings per share (EPS) | -0.43 |
| Gross Margin | 100.00% |
| Net Profit Margin | -4,555.53% |
| Debt/Equity Ratio | -55.5% |
How did VNRX perform over the long term?
See historical performance and comparison